Meeting Outline

August 19, 2020 | Click here for online streaming, requests to comment, and committee information.

Health and Human Services Interim Committee

Online Meeting, Wednesday, August 19, 2020

1:00 p.m.

(Outline version: 08/18/20, 8:10 a.m.)

Anchor location for meeting: Room 30 House Building, State Capitol Complex, Salt Lake City, Utah

*Due to public health restrictions, members of the public are not permitted to attend
the meeting at the anchor location but are invited to participate online.*

1. Committee Business

Background

- Draft minutes of the June 16, 2020, meeting

Potential Action

- Approve minutes.

2. Department of Health

The committee will consider legislation sponsored for introduction during the 2020 Sixth Special Session of the Legislature.

Background

- LEGISLATION: S.B. 6006, Department of Health Modifications *(A. Christensen)*

Presenters

- Senator Allen M. Christensen
- Committee discussion
- Public comment

Potential Action

- Recommend legislation for consideration by the Legislature

3. Pharmaceutical Reporting

The committee will consider legislation sponsored for introduction during the 2020 Sixth Special Session of the Legislature.

Background

- LEGISLATION: H.B. 6011, Pharmaceutical Reporting Amendments *(P. Ray)*

Presenters

- Representative Paul Ray
- Committee discussion
- Public comment

Potential Action

- Recommend legislation for consideration by the Legislature

4. Health Insurance Premium Subsidies

The committee will consider legislation sponsored for introduction during the 2020 Sixth Special Session of the Legislature.

Background

- LEGISLATION: H.B. 6003, Premium Subsidy Amendments *(J. Dunnigan)*

Presenters

- Representative James A. Dunnigan
- Committee discussion
- Public comment

Potential Action

- Recommend legislation for consideration by the Legislature

5. COVID-19: An Update
The committee will continue its oversight of the state's response to the COVID-19 pandemic.

Background

- Coronavirus.Utah.gov (Source: Utah Coronavirus Task Force)

- [Phased Guidelines for the General Public and Businesses to Maximize Public Health and Economic Reactivation Version 4.9](#) (Source: Governor's Office of Management and Budget et al.)

Presenters

- Introduction
  - ➢ Chair Christensen
  - ➢ Chair Daw

- Utah Department of Health
  - ➢ Rich Saunders, Interim Executive Director
  - ➢ Dr. Angela Dunn, State Epidemiologist
  - ➢ Heather Borski, Director, Division of Disease Control and Prevention
  - ➢ Nathan Checketts: Deputy Director; Director, Medicaid and Health Financing; and COVID-19 Testing Coordinator

Potential Action

- Request additional information

6. Medical Cannabis
The committee will receive reports on the implementation of medical cannabis policy and emerging issues.

Background

- BILL SUMMARIES: For summaries of 2020 medical cannabis legislation see [2020 Health and Human Services Legislation](#) and click "Cannabis." (Source: Office of Legislative Research and General Counsel)

- RELATED STATUTES
  - ➢ [Utah Medical Cannabis Act](#)
  - ➢ [Hemp and Cannabinoid Act](#)
  - ➢ [Cannabis Production Establishments](#)

Issues

- Are there recommendations for legislative action?

Presenters

- Introduction
  - ➢ Senator Evan J. Vickers

- Utah Department of Agriculture and Food
  - ➢ Commissioner Logan Wilde
  - ➢ Cody James, Manager, Industrial Hemp and Medical Cannabis Program
  - ➢ Amber Brown, Senior Policy Analyst

- Utah Department of Health
  - ➢ Dr. Marc Babitz, Deputy Director
  - ➢ Rich Oborn, Director, Center for Medical Cannabis

Potential Action

- Determine next steps

7. Opioids – Post-Surgery Prescriptions
The committee will consider draft legislation that limits the quantity of an opioid that may be prescribed following surgery.

Background

- DRAFT LEGISLATION: [Controlled Substance Amendments](#) (Rep. Ward)

Presenters

- Representative Raymond P. Ward

- Public comment

Potential Action

- Recommend amendments to and/or consideration of draft legislation

8. Ethical Drug Framework
The committee will consider a proposal to establish an ethical drug framework.

Presenters

- Representative Norman K. Thurston

Potential Action
• Identify next steps

9. Adjourn